The White House has urged the US Food and Drug Regulatory Authority (FDA) to reconsider the use of the anti-malarial drug hydroxychloroquine (HCQ) to treat COVID-19 patients. Let us tell you that FDA withdrew approval to use anti-malarial drugs, HCQ for COVID-19 last month. It stated that these drugs are not successful and effective in preventing virus infection. The FDA cited results from the clinical trial. It states that the use of this drug is not effective, and US treatment guidelines also do not support the use of these drugs in cases of COVID-19.
On behalf of the Trump administration, White House Trade Advisor Peter Navarro has asked the FDA to lift the ban on the drug. The Washington Post gave this information in a report published on Monday. The Washington Post quoted Steven Joffe, a medical ethicist at the University of Pennsylvania, said, 'A reversal (on HCQ) would be widely seen as bending to the political will of the White House.'
Earlier, US President Trump had said in his response to the condemnation of hydroxychloroquine, that it is a way of protection against the coronavirus. According to the revelations made by Trump, in response to the criticism being made to avoid the deadly infection. He described it as a way of protecting against the coronavirus. Let us tell you that Trump also took a dose of this medicine for a few days to avoid a fatal infection. President Trump had said that the reason behind calling this medicine bad is because I was promoting it.